TIF1 gamma

Product Information

TIF1-gamma is an autoantigen targeted in dermatomyositis (DM). Autoantibodies against TIF1-gamma (also known as anti-p155) have been shown to have a strong association with cancer in adult DM patients. The presence of these antibodies therefore prompt cancer screening in adults. These myositis-specific autoantibodies are also prevalent in juvenile DM patients who present with severe cutaneous involvement, although there is no cancer association here.

TIF1 gamma is a nuclear protein that belongs to the tripartite motif-containing family. The protein contains a N-terminal TRIM motif (RING-B-box-coiled-coil) that functions as an E3 ubiquitin-protein ligase for SMAD4 in the TGF-β signalling pathway – a cell growth and differentiation pathway implicated in tumour development. The C-terminal contains a PHD bromo domain that allows for transcription regulation via interaction with histones 3 and 4 of chromatin.

Patient sera comparisons by immunoblot against ELISA and immunoprecipitation assays have shown that only approximately one-third of anti-TIF1 gamma positive patients are detected by immunoblot. This is evidence for the presence of linear and conformational autoantigenic epitopes of TIF1 gamma, which is patient dependent.

AROTEC TIF1 gamma is expressed as a full-length protein in insect cells and is purified using non-denaturing conditions, conserving both critical forms of epitopes. The protein is the human sequence variant and contains a hexa-histidine purification tag.

TIF1 gamma antigen is part of a comprehensive Myositis panel developed at AROTEC.

Clinical Indications

Dermatomyositis (DM)

Certificate of Analysis

Please log in to view certificates of analysis for this item

MSDS

References

1.Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis & Rheumatism. 2006;54(11):3682-3689.

2.Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. Feb 2012;64(2):513-22.

3.Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). Mar 2008;47(3):324-8.

4.Kwiatkowska D, Reich A. The Significance of Autoantibodies in Juvenile Dermatomyositis. Biomed Res Int. 2021;2021:5513544.

5.Kobayashi I. Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review. Children (Basel). Aug 27 2024;11(9)

6.Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L. Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clin Exp Rheumatol. Nov-Dec 2019;37(6):1048-1051.

7.Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. Feb 2012;64(2):346-9.

8.Kotobuki Y, Tonomura K, Fujimoto M. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis. Immunological Medicine. 2021/01/02 2021;44(1):23-29.